Roivant Sciences [ROIV] vs Blueprint Medicines [BPMC] Detailed Stock Comparison
Roivant Sciences
NASDAQ
Loading...
Blueprint Medicines
NASDAQ
Loading...
TLDR: Quick Comparison Summary
Based on 18 vital metrics comparison: Roivant Sciences wins in 6 metrics, Blueprint Medicines wins in 12 metrics, with 0 ties. Blueprint Medicines appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Roivant Sciences | Blueprint Medicines | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 1.95 | -120.99 | Blueprint Medicines |
| Price-to-Book Ratio | 1.76 | 24.43 | Roivant Sciences |
| Debt-to-Equity Ratio | 1.93 | 208.50 | Roivant Sciences |
| PEG Ratio | -0.01 | -137.72 | Blueprint Medicines |
| EV/EBITDA | -3.29 | -53.14 | Blueprint Medicines |
| Profit Margin (TTM) | 96.86% | -27.70% | Roivant Sciences |
| Operating Margin (TTM) | -13,130.05% | -27.50% | Blueprint Medicines |
| Return on Equity | -3.32% | -47.71% | Roivant Sciences |
| Return on Assets (TTM) | -3.16% | -9.75% | Roivant Sciences |
| Free Cash Flow (TTM) | $-844.05M | $-197.22M | Blueprint Medicines |
| 1-Year Return | 5.90% | 12.60% | Blueprint Medicines |
| Price-to-Sales Ratio (TTM) | 348.30 | 14.89 | Blueprint Medicines |
| Enterprise Value | $3.77B | $8.42B | Blueprint Medicines |
| EV/Revenue Ratio | 162.21 | 14.97 | Blueprint Medicines |
| Gross Profit Margin (TTM) | 92.90% | 98.12% | Blueprint Medicines |
| Revenue per Share (TTM) | $0 | $9 | Blueprint Medicines |
| Earnings per Share (Diluted) | $-1.09 | $-2.51 | Roivant Sciences |
| Beta (Stock Volatility) | 1.15 | 0.83 | Blueprint Medicines |
Performance
Key Stats
Valuation
Financials
Short Interest
Dividends
Roivant Sciences vs Blueprint Medicines Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Roivant Sciences | 0.85% | 3.13% | 4.31% | 10.13% | 10.96% | -1.90% |
| Blueprint Medicines | 0.00% | 0.12% | 1.05% | 53.79% | 15.63% | 48.46% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Roivant Sciences | 5.90% | 220.27% | 19.46% | 19.46% | 19.46% | 19.46% |
| Blueprint Medicines | 12.60% | 149.54% | 73.38% | 370.76% | 598.65% | 598.65% |
Performance & Financial Health Analysis: Roivant Sciences vs Blueprint Medicines
| Metric | ROIV | BPMC |
|---|---|---|
| Market Information | ||
| Market Cap | $8.09B | $8.37B |
| Market Cap Category | Mid cap | Mid cap |
| 10 Day Avg. Volume | 5,274,610 | 5,799,940 |
| 90 Day Avg. Volume | 5,127,443 | 4,343,357 |
| Last Close | $11.85 | $129.46 |
| 52 Week Range | $8.73 - $13.06 | $73.04 - $129.65 |
| % from 52W High | -9.23% | -0.15% |
| All-Time High | $16.76 (Dec 20, 2021) | $129.65 (Jul 16, 2025) |
| % from All-Time High | -29.30% | -0.15% |
| Growth Metrics | ||
| Quarterly Revenue Growth | -0.73% | 0.56% |
| Quarterly Earnings Growth | -0.96% | -0.99% |
| Financial Health | ||
| Profit Margin (TTM) | 0.97% | -0.28% |
| Operating Margin (TTM) | -131.30% | -0.28% |
| Return on Equity (TTM) | -0.03% | -0.48% |
| Debt to Equity (MRQ) | 1.93 | 208.50 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $6.74 | $5.30 |
| Cash per Share (MRQ) | $7.19 | $8.92 |
| Operating Cash Flow (TTM) | $-223,083,000 | $-145,552,000 |
| Levered Free Cash Flow (TTM) | $-2,765,250,200 | $-20,779,750 |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | N/A |
| Last 12-Month Dividend | N/A | N/A |
Valuation & Enterprise Metrics Analysis: Roivant Sciences vs Blueprint Medicines
| Metric | ROIV | BPMC |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 1.95 | -120.99 |
| Forward P/E | -9.96 | -137.72 |
| PEG Ratio | -0.01 | -137.72 |
| Price to Sales (TTM) | 348.30 | 14.89 |
| Price to Book (MRQ) | 1.76 | 24.43 |
| Market Capitalization | ||
| Market Capitalization | $8.09B | $8.37B |
| Enterprise Value | $3.77B | $8.42B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 162.21 | 14.97 |
| Enterprise to EBITDA | -3.29 | -53.14 |
| Risk & Other Metrics | ||
| Beta | 1.15 | 0.83 |
| Book Value per Share (MRQ) | $6.74 | $5.30 |
Financial Statements Comparison: Roivant Sciences vs Blueprint Medicines
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | ROIV | BPMC |
|---|---|---|
| Revenue/Sales | $2.17M | $149.41M |
| Cost of Goods Sold | $154,000 | $2.80M |
| Gross Profit | $2.02M | $146.61M |
| Research & Development | $152.92M | $91.89M |
| Operating Income (EBIT) | $-284.92M | $-41.09M |
| EBITDA | $-264.70M | $23.55M |
| Pre-Tax Income | $-269.26M | $1.29M |
| Income Tax | $4.65M | $789,000 |
| Net Income (Profit) | $-273.91M | $496,000 |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | ROIV | BPMC |
|---|---|---|
| Cash & Equivalents | $2.72B | $122.25M |
| Total Current Assets | $5.00B | $702.07M |
| Total Current Liabilities | $149.41M | $250.58M |
| Long-Term Debt | $90.33M | $409.17M |
| Total Shareholders Equity | $5.19B | $342.13M |
| Retained Earnings | $116.06M | $-2.41B |
| Property, Plant & Equipment | $101.08M | $97.66M |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | ROIV | BPMC |
|---|---|---|
| Operating Cash Flow | $-110.68M | $13.41M |
| Capital Expenditures | $-811,000 | $-1.83M |
| Free Cash Flow | $-173.38M | $-56.31M |
| Debt Repayment | $0 | $-4.11M |
| Common Stock Repurchase | $-295.45M | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | ROIV | BPMC |
|---|---|---|
| Shares Short | 38.31M | 3.13M |
| Short Ratio | 6.62 | 0.62 |
| Short % of Float | 0.08% | 0.05% |
| Average Daily Volume (10 Day) | 5,274,610 | 5,799,940 |
| Average Daily Volume (90 Day) | 5,127,443 | 4,343,357 |
| Shares Outstanding | 695.94M | 63.71M |
| Float Shares | 400.09M | 60.00M |
| % Held by Insiders | 0.26% | 0.01% |
| % Held by Institutions | 0.77% | 1.09% |
Dividend Analysis & Yield Comparison: Roivant Sciences vs Blueprint Medicines
| Metric | ROIV | BPMC |
|---|---|---|
| Last 12-Month Dividend | N/A | N/A |
| Last 12-Month Dividend Yield | N/A | N/A |
| 3-Year Avg Annual Dividend | N/A | N/A |
| 3-Year Avg Dividend Yield | N/A | N/A |
| 3-Year Total Dividends | N/A | N/A |
| Ex-Dividend Date | N/A | N/A |